西藏地区膀胱尿路上皮癌患者 GATA-3 和 H3K27me3 的表达及其临床意义

尼玛卓玛; 肖雨; 罗含欢; 多布啦; 王寒; 达珍; 斯朗江村; 郭平平; 廖瑞倩

doi:10.12290/xhyxzz.2023-0595

西藏地区膀胱尿路上皮癌患者 GATA-3 和 H3K27me3 的表达及其临床意义

doi: 10.12290/xhyxzz.2023-0595

1 西藏自治区人民医院病理科, 拉萨 850000
2 中国医学科学院北京协和医院病理科, 北京 100730
3 西藏自治区人民医院泌尿外科, 拉萨 850000

基金项目:

西藏自治区自然科学基金组团式援藏医学项目（XZ2020ZR-ZY23[Z]）

详细信息

通讯作者:
肖雨,E-mail: xiaoyu@pumch.cn

中图分类号: G737；R446.8
计量
- 文章访问数: 26
- HTML全文浏览量: 4
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2023-12-06
- 录用日期: 2024-01-22
- 网络出版日期: 2024-03-18

Expression and Significance of GATA-3、 H3K27me3 in Tibet with Bladder Urothelial Carcinoma

1 Department of Pathology, Tibet Autonomous Region People's Hospital, Lhasa 850000, China
2 Department of Pathology, Peking Union Medical College, Beijing Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
3 Department of Urology Surgery, Tibet Autonomous Region People's Hospital, Lhasa 850000, China

Funds:

Tibet Natural Science Funding Committee Grant (XZ2020ZR-ZY23[Z])

摘要

摘要: 目的探讨西藏地区膀胱尿路上皮癌(bladder urothelialcarcinoma, BUC)患者 GATA-3 和 H3K27me3 的表达及其临床意义。方法回顾性收集西藏自治区人民医院 2016 年 1 月-2021 年 12 月间行膀胱癌手术的 BUC 患者的临床资料及其病理组织,以经尿道膀胱黏膜活检术获取的正常膀胱组织作为对照,采用免疫组化染色方法检测 BUC 和正常膀胱组织中 GATA-3 和 H3K27me3 的表达水平,同时结合临床病理特征分析 GATA-3 和 H3K27me3 在藏族 BUC 患者中的表达差异。结果共入选 BUC患者 70 例, 其中男性 51 例,女性 19 例,平均年龄(60.5±12.0)岁,同时收集同期正常膀胱组织标本 20 份,均来自于藏族患者。免疫组化检测结果显示, GATA-3 在 BUC及正常膀胱组织中高表达率分别为 70%(49/70)和 100%(20/20), GATA-3 高表达与男性、病理分级低、组织非浸润相关(P 均<0.05); H3K27me3 在 BUC 及正常膀胱组织中高表达率分别为 45.7%(32/70)和 20%(4/20), H3K27me3 高表达仅与男性相关(P<0.05)。结论 GATA-3 在西藏地区 BUC 患者膀胱组织中表达下调,且随着肿瘤级别的升高表达显著下调,提示 GATA-3 可能参与 BUC 发生、发展并与其恶性程度相关,为临床诊疗及判断疾病预后提供了参考。H3K27me3 在西藏地区 BUC 患者膀胱组织中表达上调,提示 H3K27me3 有望成为诊断膀胱尿路上皮癌的新型免疫标志物。
- 西藏地区 /
- 膀胱尿路上皮癌 /
- 临床病理特征 /
- GATA-3 /
- H3K27me3
Abstract: Objective To investigate the expression and clinical significance of GATA-3 and H3K27me3 in Tibet with bladder urothelial carcinoma (BUC). Methods BUC and normal bladder tissues were collected retrospectively from January 2016 to December 2021 in the People's Hospital of Tibet Autonomous Region. The expression of GATA-3 and H3K27me3 in both tissues was detected by immunohistochemical method, and the clinical and pathological characteristics were statistically analyzed. Results A total of 70 patients with BUC were selected, including 51 males and 19 females, with an average age of (60.5± 12.0) years. At the same time, 20 normal bladder tissue samples were collected during the same period. All cases were Tibetan patients. Immunohistochemistry results showed that the high expression rate of GATA-3 in BUC and normal bladder tissue was 70% (49/70) and 100% (20/20), respectively. High expression of GATA-3 was associated with male, low pathological grade, and non invasive tissue (P<0.05). The high expression rate of H3K27me3 in BUC and normal bladder tissue was 45.7% (32/70) and 20% (4/20), respectively. High expression of H3K27me3 was only associated with male (P<0.05). Conclusions The expression of GATA-3 is down regulated in patients with BUC in Tibet, and significantly down regulated with the increase of tumor grade, suggesting that GATA-3 may be involved in the occurrence and development of BUC and related to its malignancy, providing a reference for clinical diagnosis and treatment and judging disease prognosis. The expression of H3K27me3 in BUC in Tibet is higher than that in normal bladder tissue, suggesting that H3K27me3 may be a new immune marker for diagnosis of bladder urothelial carcinoma.
- Tibet /
- Bladder urothelial carcinoma /
- Clinicopathological characteristics /
- GATA-3 /
- H3K27me3

HTML全文

参考文献(22)

[1]	国家癌症中心,国家肿瘤质控中心膀胱癌质控专家委员会.中国膀胱癌规范诊疗质量控制指标(2022版)[J].中华肿瘤杂志, 2022,44(10):1003-1010. DOI: 10.3760/cma.j.cn112152-20220803-00531.
[2]	Najafabadi M K, Mirzaeian E, Montazerin S M, et al. Role of GATA-3 in Tumor Diagnosis:A Review[J]. Pathology Research and Practice, 2021:153611. DOI:0.1016/j.prp. 2021.153611.
[3]	徐静纯,王聪.H3K27me3在肿瘤中的研究进展[J].南京医科大学学报(自然科学版),2022,42(06):897-902.
[4]	李幸达,孙卫兵,蒋葵.GATA-3在上尿路上皮癌中的表达及临床意义[J].临床泌尿外科杂志,2020,35(02):112-116.
[5]	Samal S, Patnaik A, Sahu F, Purkait S. Altered expression of pigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas-prognostic biomarkers or routine practice. Folia Neuropathol.2020;58(2):133-142. DOI: 10.5114/fn.2020.96970.
[6]	谢轶群,裔海鹰,施俊义,等. GATA-3在乳腺癌中的表达及其与预后的关系[J].中国癌症杂志, 2010,20(12):911-914.
[7]	朱匡政. T-bet、GATA-3在膀胱尿路上皮癌组织中的检测及临床意义[D].西北民族大学,2020.DOI:10.27408/d.cnki.gxmzc. 2020. 000495.
[8]	冯春. AR、GATA-3在膀胱尿路上皮癌的表达及与临床病理的关系[D].青海大学, 2019. DOI: 10.27740/d.cnki.gqhdx.2019. 000319.
[9]	袁丽倩,陈曲,李红英.膀胱尿路上皮癌中GATA-3的表达及与Ki-67的相关性分析[J].诊断病理学志,2021,28(08):635-638.
[10]	开蕾,张二春,彭钧.膀胱尿路上皮癌组织CD44V6、GATA-3的表达变化及与肿瘤病理分级的关系[J].山东医药,2016,56(09):75-76.
[11]	钟凯华. GATA-3蛋白在调控膀胱尿路上皮癌生物学行为中的作用及与复发的关系研究[J].解剖学研究, 2017, 39(1):9-12.
[12]	Inoue S, Mizushima T, Fujita K, et al. GATA3 Immunehistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator[J]. Human Pathology, 2017. DOI: 10.1016/j.humpath.2017.04.003.
[13]	Huber JP, Gonzales-van Horn SR, Roybal KT, et al. IFN-α suppresses GATA3 transcription from a distal exon and promotes H3K27 trimethylation of the CNS-1 enhancer in human Th2 cells[J]. J Immunol. 2014 Jun 15;192(12):5687-94. DOI: 10.4049/jimmunol.1301908.
[14]	Levy S, Somasundaram L, Raj IX, et al. dCas9 fusion to computerdesigned PRC2 inhibitor reveals functional TATA box in distal promoter region[J]. Cell Rep. 2022 Mar 1;38(9):110457. DOI: 10.1016/j.celrep.2022.110457.
[15]	Wei Y, Xia W, Zhang Z, et al. Loss of Trimethylation at Lysine 27 of Histone H3 Is a Predictor of Poor Outcome in Breast, Ovarian, and Pancreatic Cancers[J]. Mol Carcinog. 2008 Sep; 47(9):701- 706. DOI: 10.1002/mc.20413
[16]	He WP, Li Q, Zhou J, et al. Decreased expression of H3K27me3 in human ovarian carcinomas correlates with more aggressive tumor behavior and poor patient survival. Neoplasma. 2015;62(6):932-7. DOI: 10.4149/neo_2015_113
[17]	Cai MY, Tong ZT, Zhu W, et al. H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma[J]. Mol Med, 2011, 17(11-12):1137-1145. DOI: 10.2119/molmed.2011.00054
[18]	Lin S, Zhou M, Li Y, et al. H3K27 trimethylation and H3K9 dimethylation as poor prognostic markers for patients with esophageal squamous cell carcinoma[J]. Int J Clin Exp Pathol. 2019 Jul 1;12(7):2657- 2664. eCollection 2019.
[19]	Luciano DC, Kristian H. Transcriptional regulation by Polycomb group proteins[J]. Nat Struct Mol Biol,2013,20(10):1147-1155. DOI: 10.1038/nsmb.2669
[20]	罗含欢, 霍真, 王倩, 等.西藏地区脑膜瘤临床病理观察[J].中国医学科学院学报, 2022,44(04):621-627.
[21]	罗含欢, 师杰, 边巴扎西, 等. 西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义[J]. 协和医学杂志, 2022.13(1):DOI: 10.12290 /xhyxzz.2021- 0727.
[22]	Liu JY, Li YH, Liao YJ, et al. High Expression of H3K27me3 Is an Independent Predictor of Worse Outcome in Patients with Urothelial Carcinoma of Bladder Treated with Radical Cystectomy[J]. Biomed Res Int. 2013; 2013:390482. DOI: 10.1155/2013/390482.

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 26
HTML全文浏览量: 4
PDF下载量: 3
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

西藏地区膀胱尿路上皮癌患者 GATA-3 和 H3K27me3 的表达及其临床意义

doi: 10.12290/xhyxzz.2023-0595

通讯作者:
肖雨,E-mail: xiaoyu@pumch.cn

计量

Expression and Significance of GATA-3、 H3K27me3 in Tibet with Bladder Urothelial Carcinoma

计量

目录

留言板

西藏地区膀胱尿路上皮癌患者 GATA-3 和 H3K27me3 的表达及其临床意义

doi: 10.12290/xhyxzz.2023-0595

通讯作者: 肖雨,E-mail: xiaoyu@pumch.cn

计量

出版历程

Expression and Significance of GATA-3、 H3K27me3 in Tibet with Bladder Urothelial Carcinoma

计量

出版历程

目录

通讯作者:
肖雨,E-mail: xiaoyu@pumch.cn